Table 9 |
||||
|
action profile of human insulin and human insulin analogs |
||||
|
Human Insulins |
Insulin Type |
Onset |
Action peak |
Duration of action |
|
|
||||
|
Rapid-acting insulin analogs |
Glulisine (Apidra®) |
<5-15 minutes |
1 hour |
4 hours |
|
Lispro (Humalog®) |
<15 minutes |
0.5-1.5 hour |
2-4 hours |
|
|
Aspart (NovoRapid®) |
5-10 minutes |
1-3 hours |
3-5 hours |
|
|
Short acting insulin |
Regular (Novolin® R, Humulin® R) |
30-60 minutes |
2-3 hours |
3-6 hours |
|
Intermediate acting insulin |
NPH (Novolin® N Humulin® N) |
2-4 hours |
4-10 hours |
10-16 hours |
|
Long-acting insulin analogs |
Glargine (Lantus®) |
1-2 hours |
None |
Up to 24 hours |
|
Detemir (Levemir®) |
1-2 hours |
None |
Up to 24 hours |
|
|
|
||||
|
This table presents only a partial list of commercial medications of various drugs and does not represent a specific recommendation of any commercial brand. |
||||
|
Lerario et al. Diabetology & Metabolic Syndrome 2010 2:35 doi:10.1186/1758-5996-2-35 |
||||
